Brokerages Anticipate Qiagen NV (QGEN) to Post $0.26 EPS

Equities research analysts expect Qiagen NV (NYSE:QGEN) to announce earnings of $0.26 per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Qiagen’s earnings. The highest EPS estimate is $0.27 and the lowest is $0.25. Qiagen also reported earnings of $0.26 per share during the same quarter last year. The business is expected to announce its next quarterly earnings report on Wednesday, May 1st.

According to Zacks, analysts expect that Qiagen will report full-year earnings of $1.45 per share for the current year, with EPS estimates ranging from $1.43 to $1.47. For the next financial year, analysts forecast that the firm will post earnings of $1.64 per share, with EPS estimates ranging from $1.60 to $1.65. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Qiagen.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Monday, February 4th. The company reported $0.40 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.40. Qiagen had a net margin of 12.68% and a return on equity of 12.15%. The firm had revenue of $403.20 million for the quarter, compared to the consensus estimate of $409.32 million. During the same period in the previous year, the company earned $0.43 earnings per share. The company’s quarterly revenue was up 1.6% on a year-over-year basis.

QGEN has been the subject of a number of recent analyst reports. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a report on Tuesday, January 29th. UBS Group began coverage on Qiagen in a research report on Friday, March 15th. They set a “neutral” rating and a $42.00 target price for the company. Finally, Jefferies Financial Group reiterated a “neutral” rating on shares of Qiagen in a report on Monday, January 21st. Eight investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $41.17.

Several institutional investors and hedge funds have recently added to or reduced their stakes in QGEN. Sycomore Asset Management purchased a new position in shares of Qiagen during the fourth quarter worth $86,182,000. American Century Companies Inc. raised its stake in shares of Qiagen by 111.7% in the fourth quarter. American Century Companies Inc. now owns 995,508 shares of the company’s stock valued at $34,295,000 after acquiring an additional 525,268 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Qiagen by 4.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 12,615,185 shares of the company’s stock valued at $434,593,000 after acquiring an additional 481,606 shares in the last quarter. Millennium Management LLC raised its stake in shares of Qiagen by 172.7% in the fourth quarter. Millennium Management LLC now owns 650,831 shares of the company’s stock valued at $22,421,000 after acquiring an additional 412,211 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Qiagen by 116.5% in the fourth quarter. Jane Street Group LLC now owns 685,032 shares of the company’s stock valued at $23,599,000 after acquiring an additional 368,567 shares in the last quarter. Institutional investors and hedge funds own 64.77% of the company’s stock.

Shares of Qiagen stock opened at $39.92 on Friday. The stock has a market cap of $9.09 billion, a price-to-earnings ratio of 30.10, a PEG ratio of 2.49 and a beta of 0.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.05 and a current ratio of 2.22. Qiagen has a 12-month low of $31.10 and a 12-month high of $40.42.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Recommended Story: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on Qiagen (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit